50508-54-8

Basic information

• Product Name: 4-BENZYLOXY-3-CHLORO NITROBENZENE 97
• Synonyms: 4-BENZYLOXY-3-CHLORO NITROBENZENE 97;4-benzyloxy-3-chloronitrobenzne;4-Benzyloxy-3-chloronitrobenzene;2-chloro-4-nitro-1-(phenylmethoxy)Benzene
• CAS NO: 50508-54-8
• Molecular Formula: C₁₃H₁₀ClNO₃
• Molecular Weight: 263.68
• Product Categories: Nitro Compounds;Nitrogen Compounds;Organic Building Blocks
• Mol File: 50508-54-8.mol
• Article Data: 17

Chemical Properties

• Melting Point: 115-119 °C(lit.)
• Boiling Point: 403.2°C at 760 mmHg
• Flash Point: 197.6°C
• Appearance: /
• Density: 1.332g/cm³
• Vapor Pressure: 2.41E-06mmHg at 25°C
• Refractive Index: 1.612
• CAS DataBase Reference: 4-BENZYLOXY-3-CHLORO NITROBENZENE 97(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BENZYLOXY-3-CHLORO NITROBENZENE 97(50508-54-8)
• EPA Substance Registry System: 4-BENZYLOXY-3-CHLORO NITROBENZENE 97(50508-54-8)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 50508-54-8(Hazardous Substances Data)

Usage

General Description

4-Benzyloxy-3-chloro nitrobenzene 97 is a chemical compound that consists of a nitro group, a chloro group, and a benzyloxy group attached to a benzene ring. It is often used as an intermediate in the synthesis of various compounds, including pharmaceuticals and agrochemicals. 4-BENZYLOXY-3-CHLORO NITROBENZENE 97 is commonly employed as a building block in organic synthesis, and its high purity grade of 97% makes it suitable for use in research and development applications. The 4-benzyloxy-3-chloro nitrobenzene 97 chemical is known for its potential applications in the pharmaceutical industry for the development of new drugs, as well as in the production of specialty chemicals. Overall, this chemical compound has versatile synthetic applications and is valued for its purity and high quality.

InChI:InChI=1/C13H10ClNO3/c14-12-8-11(15(16)17)6-7-13(12)18-9-10-4-2-1-3-5-10/h1-8H,9H2

Upstream product

• 350-30-1 3-chloro-4-fluoronitrobenzene 
• 100-51-6 benzyl alcohol 
• 619-08-9 2-chloro-4-nitrophenol 
• 100-39-0 benzyl bromide 
• 38731-70-3 sodium salt of 2-chloro-4-nitrophenol 
• 100-44-7 benzyl chloride 

Relevant articles and documents

Design, synthesis and evaluation of tetrahydrocarbazole derivatives as potential hypoglycemic agents

Two series of tetrahydrocarbazole derivatives have been designed and synthesized based on ZG02, a promising candidate developed in our previous studies. The newly prepared compounds were screened for glucose consumption activity in HepG2 cell lines. Aza-tetrahydrocarbazole compound 12b showed the most potent hypoglycemic activity with a 45% increase in glucose consumption when compared to the solvent control, which had approximately 1.2-fold higher activity than the positive control compounds (metformin and ZG02). An investigation of the potential mechanism indicated that 12b may exhibit hypoglycemic activity via activation of the AMPK pathway. Metabolic stability assays revealed that 12b showed good stability profiles in both artificial gastrointestinal fluids and blood plasma from SD rats. An oral glucose tolerance test (OGTT) was performed and the results further confirmed that 12b was a potent hypoglycemic agent.

Indole compound as well as preparation method, pharmaceutical composition and application thereof

The invention discloses an indole compound as well as a preparation method, a pharmaceutical composition and an application thereof. Specifically, the invention relates to an indole derivative as shown in a general formula I and a medicinal salt thereof, a preparation method of the indole derivative, a composition containing one or more compounds, and applications of the compounds in preparation of medicines for preventing and/or treating diseases related to IDO1 and/or TDO.

Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery

Tropical protozoal infections are a significant cause of morbidity and mortality worldwide; four in particular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) have an estimated combined burden of over 87 million disability-adjusted life years. New drugs are needed for each of these diseases. Building on the previous identification of NEU-617 (1) as a potent and nontoxic inhibitor of proliferation for the HAT pathogen (Trypanosoma brucei), we have now tested this class of analogs against other protozoal species: T. cruzi (Chagas disease), Leishmania major (cutaneous leishmaniasis), and Plasmodium falciparum (malaria). Based on hits identified in this screening campaign, we describe the preparation of several replacements for the quinazoline scaffold and report these inhibitors' biological activities against these parasites. In doing this, we have identified several potent proliferation inhibitors for each pathogen, such as 4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-6-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)quinoline-3-carbonitrile (NEU-924, 83) for T. cruzi and N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)cinnolin-4-amine (NEU-1017, 68) for L. major and P. falciparum.